scispace - formally typeset
B

Boakye A. Boatin

Researcher at World Health Organization

Publications -  43
Citations -  3192

Boakye A. Boatin is an academic researcher from World Health Organization. The author has contributed to research in topics: Onchocerciasis & Onchocerca volvulus. The author has an hindex of 29, co-authored 43 publications receiving 3026 citations. Previous affiliations of Boakye A. Boatin include University of Ghana & McGill University.

Papers
More filters
Journal ArticleDOI

A research agenda for helminth diseases of humans: the problem of helminthiases.

TL;DR: The forces driving the persistence of helminthiases as a public health problem despite the many control initiatives that have been put in place are provided; the main obstacles that impede progress are identified; and recent advances, opportunities, and challenges for the understanding of the biology, epidemiology, and control of these infections are discussed.
Journal ArticleDOI

An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana

TL;DR: The results indicate that the significant microfilaridermias that persist despite multiple treatments with ivermectin are mainly attributable to the non-response of the adult female worms and not to inadequate drug exposure or other factors, and justify the routine monitoring of treatment efficacy in any iverMectin-based programme of disease control.
Journal ArticleDOI

Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort study

TL;DR: Analysis of RANTES compound genotype frequencies between HIV-positive and exposed-uninfected participants of the Multicenter AIDS Cohort Study and rates of progression to AIDS for MACS seroconverters implicate the RantES-403A allele as a risk factor for HIV transmission and as a protective factor for AIDS progression.
Journal ArticleDOI

A research agenda for helminth diseases of humans: intervention for control and elimination.

TL;DR: To achieve the goals of morbidity reduction or elimination of infection, novel tools need to be developed, including more efficacious drugs, vaccines, and/or antivectorial agents, new diagnostics for infection and assessment of drug efficacy, and markers for possible anthelmintic resistance.